Literature DB >> 34661155

Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia.

Meng Li1, Ari M Melnick1.   

Abstract

In this issue of Blood Cancer Discovery, Yan and colleagues discovered that mitochondrial deacylase, SIRT5, is required in AML cells to support mitochondrial oxidative phosphorylation, maintain redox homeostasis, and drive glutaminolysis. The new SIRT5 inhibitor, NRD167, can efficiently target SIRT5 in AMLs at micromolar range and may constitute a novel therapeutic approach to improve clinical outcomes of patients with AML. See related article by Yan et al., p. 266. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID： 34661155      PMCID： PMC8513906          DOI： 10.1158/2643-3230.BCD-21-0026

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  11 in total

Review 1.  The Mitochondrial Acylome Emerges: Proteomics, Regulation by Sirtuins, and Metabolic and Disease Implications.

Authors:  Chris Carrico; Jesse G Meyer; Wenjuan He; Brad W Gibson; Eric Verdin
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

2.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.

Authors:  Meng Li; Ying-Ling Chiang; Costas A Lyssiotis; Matthew R Teater; Jun Young Hong; Hao Shen; Ling Wang; Jing Hu; Hui Jing; Zhengming Chen; Neeraj Jain; Cihangir Duy; Sucharita J Mistry; Leandro Cerchietti; Justin R Cross; Lewis C Cantley; Michael R Green; Hening Lin; Ari M Melnick
Journal:  Cancer Cell       Date:  2019-06-10       Impact factor: 31.743

3.  Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.

Authors:  Courtney L Jones; Brett M Stevens; Daniel A Pollyea; Rachel Culp-Hill; Julie A Reisz; Travis Nemkov; Sarah Gehrke; Fabia Gamboni; Anna Krug; Amanda Winters; Shanshan Pei; Annika Gustafson; Haobin Ye; Anagha Inguva; Maria Amaya; Mohammad Minhajuddin; Diana Abbott; Michael W Becker; James DeGregori; Clayton A Smith; Angelo D'Alessandro; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2020-08-20       Impact factor: 24.633

Review 4.  Acute myeloid leukaemia.

Authors:  Asim Khwaja; Magnus Bjorkholm; Rosemary E Gale; Ross L Levine; Craig T Jordan; Gerhard Ehninger; Clara D Bloomfield; Eli Estey; Alan Burnett; Jan J Cornelissen; David A Scheinberg; Didier Bouscary; David C Linch
Journal:  Nat Rev Dis Primers       Date:  2016-03-10       Impact factor: 52.329

5.  SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks.

Authors:  Matthew J Rardin; Wenjuan He; Yuya Nishida; John C Newman; Chris Carrico; Steven R Danielson; Ailan Guo; Philipp Gut; Alexandria K Sahu; Biao Li; Radha Uppala; Mark Fitch; Timothy Riiff; Lei Zhu; Jing Zhou; Daniel Mulhern; Robert D Stevens; Olga R Ilkayeva; Christopher B Newgard; Matthew P Jacobson; Marc Hellerstein; Eric S Goetzman; Bradford W Gibson; Eric Verdin
Journal:  Cell Metab       Date:  2013-12-03       Impact factor: 27.287

6.  SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.

Authors:  Anca Franzini; Anthony D Pomicter; Dongqing Yan; Brayden J Halverson; Orlando Antelope; Clinton C Mason; Jonathan M Ahmann; Anna V Senina; Nadeem A Vellore; Courtney L Jones; Matthew S Zabriskie; Hein Than; Michael J Xiao; Alexandria van Scoyk; Ami B Patel; Phillip M Clair; William L Heaton; Shawn C Owen; Joshua L Andersen; Christina M Egbert; Julie A Reisz; Angelo D'Alessandro; James E Cox; Kevin C Gantz; Hannah M Redwine; Siddharth M Iyer; Jamshid S Khorashad; Nima Rajabi; Christian A Olsen; Thomas O'Hare; Michael W Deininger
Journal:  Blood Cancer Discov       Date:  2019-12-02

7.  Impact of the Dual Deletion of the Mitochondrial Sirtuins SIRT3 and SIRT5 on Anti-microbial Host Defenses.

Authors:  Tytti Heinonen; Eleonora Ciarlo; Didier Le Roy; Thierry Roger
Journal:  Front Immunol       Date:  2019-10-01       Impact factor: 7.561

8.  SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.

Authors:  Jiao Ma; Bin Liu; Dan Yu; Yong Zuo; Rong Cai; Jianmin Yang; Jinke Cheng
Journal:  Br J Haematol       Date:  2019-06-24       Impact factor: 6.998

9.  Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer.

Authors:  Yashira L Negrón Abril; Irma R Fernandez; Jun Young Hong; Ying-Ling Chiang; Dennis A Kutateladze; Qingjie Zhao; Min Yang; Jing Hu; Sushabhan Sadhukhan; Bo Li; Bin He; Brenna Remick; Jessica Jingyi Bai; James Mullmann; Fangyu Wang; Viviana Maymi; Ravi Dhawan; Johan Auwerx; Teresa Southard; Richard A Cerione; Hening Lin; Robert S Weiss
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 8.756

Review 10.  Extinguishing the Embers: Targeting AML Metabolism.

Authors:  Rachel Culp-Hill; Angelo D'Alessandro; Eric M Pietras
Journal:  Trends Mol Med       Date:  2020-10-26       Impact factor: 11.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.